Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD5 | P21918 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23602362 | 1.00 | PIK3CD (0.37) | PIK3CDALDH1A1CYP2D6GBA1DRD2 | |
| SCHEMBL23695847 | 0.86 | PIK3CD (0.38) | PIK3CDALDH1A1CYP2D6GBA1SMYD3 | |
| SCHEMBL23945856 | 0.86 | PIK3CD (0.38) | PIK3CDALDH1A1CYP2D6GBA1SMYD3 | |
| SCHEMBL26478671 | 0.86 | GUSB (0.46) | GBA1 | |
| SCHEMBL25928048 | 0.85 | GBA1 (0.33) | GBA1DRD2SMN1; SMN2DRD1DRD4 | |
| SCHEMBL23946046 | 0.85 | GBA1 (0.33) | GBA1DRD2SMN1; SMN2DRD1DRD4 | |
| SCHEMBL23945304 | 0.85 | PIK3CD (0.46) | PIK3CDALDH1A1 | |
| SCHEMBL22794635 | 0.84 | PIK3CD (0.52) | PIK3CDALDH1A1CYP2D6SMYD3 | |
| SCHEMBL18926688 | 0.84 | PIK3CD (0.52) | PIK3CDALDH1A1CYP2D6SMYD3 | |
| SCHEMBL25730461 | 0.83 | GLB1 (0.32) | PIK3CDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885ALDH1A1 2776/4885CYP2D6 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.